Testing for Mycoplasma Genitalium and Using Doxycycline as First-Line Therapy at Initial Presentations for Non-Gonococcal Urethritis (NGU) Correlate with Reductions in Persistent NGU.

Kelly A JohnsonMadeline SankaranRobert P KohnOliver BaconStephanie E Cohen

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

We found that the odds of return clinic visits for persistent non-gonococcal urethritis (pNGU) were significantly lower (OR 0.4, 95% CI 0.3-0.6, p < 0.0001) after implementing: (1) testing for Mycoplasma genitalium during initial evaluations for non-gonococcal urethritis (NGU) and (2) switching from azithromycin to doxycycline as first-line NGU treatment.

Keyphrases

respiratory tract
primary care
quality improvement
stem cells
replacement therapy